Focal Interest
Focal Interest

Clinical trial

  1. ALSFRS-R trial analysis methods varied widely across ALS studies
  2. Olutasidenib showed disease control in IDH1-mutated chondrosarcoma
    Phase 1b/2 trial of olutasidenib in IDH1-mutated chondrosarcoma shows disease control without dose-limiting toxicities; 52% stable disease rate in recurrent/metastatic disease.
  3. Zuranolone was approved for postpartum depression, not major depressive disorder
    Analysis of zuranolone approval reveals how fast-track designations and reduced evidentiary thresholds in drug regulation may inadequately balance innovation with public health protection.
  4. No evidence of increased gaming-related problems with long-term use of a video game therapeutic: Exploratory endpoint findings from a randomized controlled trial
    Long-term use of a video game therapeutic for depression showed no increase in gaming-related problems, with deterioration rates low across all study arms.
  5. Hypodermoclysis appears generally safe in advanced cancer
    Hypodermoclysis shows favorable safety and feasibility for hydration in advanced cancer patients receiving palliative care, with mild complications in 17% of cases and no consistent survival benefits.
  6. Meloxicam approval in cats is questioned over kidney risk and missing trial data
    Examine injectable meloxicam approval for cats, regulatory data discrepancies, acute kidney injury risks, and pharmaceutical sponsorship conflicts in veterinary medicine.
  7. MuST AKT was feasible and acceptable in a pilot trial
    MuST AKT pilot trial tests structured intervention to increase living donor kidney transplants through multidisciplinary support and social network engagement.
  8. Adjusted light color temperature lowered stress and anxiety
    Randomized controlled trial examining medium-warm white light effects on stress, anxiety, and psychological well-being in high-risk pregnant women undergoing non-stress testing procedures.
  9. Critically ill COVID-19 trial participants often lacked understanding
    Qualitative study examining COVID-19 ICU patients' experiences in REMAP-CAP Japan trial, revealing significant barriers to informed consent comprehension in critical care settings.
  10. PET/CT lesion profiles matched tuberculosis treatment outcomes in marmosets
    PET/CT-derived multivariate lesion profiles in M. tuberculosis–infected marmosets predict clinical regimen performance, distinguish cavitary granuloma responses, and outperform bacterial burden.
  11. FMT with immunotherapy showed activity in NSCLC and melanoma
    Phase 2 trial: donor FMT plus first-line ICI in NSCLC and melanoma showed high ORRs and implicates loss of specific bacterial taxa in association with response.